Compare SOBR & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOBR | SCNI |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 2.9M |
| IPO Year | N/A | N/A |
| Metric | SOBR | SCNI |
|---|---|---|
| Price | $0.84 | $0.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 250.4K | 60.4K |
| Earning Date | 11-12-2025 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | $364,164.00 | ★ $1,147,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.03 |
| Revenue Growth | 98.07 | ★ 303.87 |
| 52 Week Low | $0.83 | $0.61 |
| 52 Week High | $14.20 | $6.18 |
| Indicator | SOBR | SCNI |
|---|---|---|
| Relative Strength Index (RSI) | 28.32 | 41.41 |
| Support Level | $0.83 | $0.75 |
| Resistance Level | $0.91 | $0.86 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 1.53 | 13.87 |
Sobr Safe Inc provides non-invasive technology to quickly and humanely identify the presence of alcohol in individuals. Its technologies are integrated within robust and scalable data platform, producing statistical and measurable user and business data. It developed the scalable, patent-pending ea4 software platform for non-invasive alcohol detection and identity verification, a solution that has current and potential applications. It generates revenue through various combinations of software products and services which include the sale of cloud-based software solutions, detection and data collection hardware devices, and cloud-based data reporting and analysis services.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.